Enhancing treatment of mdr cancer with adenosine a3 antagonists
Номер патента: EP1515719A2
Опубликовано: 23-03-2005
Автор(ы): Edward Leung, Pier Andrea Borea, Pier Giovanni Baraldi, Shih-Fong Chen
Принадлежит: King Pharmaceuticals Research and Development Inc
Опубликовано: 23-03-2005
Автор(ы): Edward Leung, Pier Andrea Borea, Pier Giovanni Baraldi, Shih-Fong Chen
Принадлежит: King Pharmaceuticals Research and Development Inc
Реферат: The present invention discloses the use of high affinity adenosine A3 receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A3 receptors and cancers expressing P-glycoprotein or MRP. In preferred embodiments, adenosine A3 receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or antibiotic chemotherapeutic agent.
Enhancing treatment of MDR (multi-drug resistance) cancer with adenosine A3 antagonists
Номер патента: NZ531327A. Автор: Pier Andrea Borea,Edward Leung,Shih-Fong Chen,Pier G Baraldi. Владелец: King Pharmaceuticals Res & Dev. Дата публикации: 2006-12-22.